Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

• Status: Recruiting
• Trial end date: 2024-10-01

Summary

This study will assess safety and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic non-small cell lung cancer.

• Phase: Phase 1

Details

• Lead Sponsor: Daiichi Sankyo, Inc.
• Collaborators: AstraZeneca; Merck Sharp & Dohme Corp.
• Treatments: Carboplatin; Pembrolizumab